Managing the diabetic patient with acute myocardial infarction

Diabetic Medicine

Volumn 15, Issue 4, 1998, Pages 276-281

  Yudkin, J S ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Archway Wing ^*

^c WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

Acute infarction; Aspirin; Diabetes mellitus; Glycaemic control; Insulin; Ocular haemorrhage; Plasminogen activator inhibitor 1; Reinfarction; Sulphonylureas; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE; SULFONYLUREA DERIVATIVE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; GLUCOSE HOMEOSTASIS; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; REVIEW;

ASPIRIN; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 0031972221     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199804)15:4<276::AID-DIA586>3.0.CO;2-O     Document Type: Review

References (46)

1. Yudkin JS. How can we best prolong life? The benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br Med J 1993; 306: 1313-1318.
2. UK Prospective Diabetes Study (UKPDS). 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in noninsulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-145.
3. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
4. Laakso M. Glycemie control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish Studies. Ann Intern Med 1996; 124: 127-130.
5. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
6. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-372.
7. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, ef al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. J Am Med Assoc 1996; 276: 1886-1892.
8. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AC, Thorgeirsson G. The Scandinavian Simvastatin Survival Study (45) Study Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
9. Burke AP, Farb A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282.
10. Oswald GA, Yudkin JS. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetic Care 1988; 11: 351-358.
11. Yudkin JS. Vascular events and diabetes: acute myocardial infarction and stroke. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International Textbook of Diabetes Mellitus. Chichester: Wiley, 1997: 1255-1279.
12. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG on behalf of GISSI-2 Investigators. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 Study. J Am Coll Cardiol 1993; 22: 1788-1794.
13. Barbash GI, White HD, Modan M, Van de Werf F for the investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 707-713.
14. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 1993; 21: 920-925.
15. Stephenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J 1993; 307: 349-353.
16. Yudkin JS, Oswald GA, McKeigue PM, Forrest RD, Jackson CA. The relationship of hospital admission and fatality from myocardial infarction to glycohaemoglobin levels. Diabetologia 1988; 31: 201-205.
17. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, ef al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 1996; 313: 652-659.
18. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
19. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, tancer 1986; i: 397-401.
20. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360.
21. Gruppo Italiano per lo Studio della Sopravivenza nell' Infarcto Miocardico. GISSI-2: a factorial randomised trial of alteplase vs streptokinase and heparin vs no heparin among 12,490 patients with acute myocardial infarction, tancef 1990; 336: 65-71.
22. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3 : a randomised trial of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
24. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
25. Ward H, Yudkin JS. Thrombolysis in patients with diabetes. - Br Med ] 1995; 310: 3-4.
26. Hansen H-HT, Kjaergaard SC, Bülow I, Fog L, Christensen PD. Thrombolytic therapy in diabetic patients with acute myocardial infarction. Diabetes Care 1996; 19: 1135-1137.
27. Pfeffer MA, Moyé LA, Braunwald E, Basta L, Brown EJ jr, Cuddy TE, Dagenais CR, Flaker GC, Geltman EM, Gersh BJ, Goldman S, Lamas GA, Packer M, Rouleau JL, Rutherford JD, Steingart RM, Wertheimer JH for the SAVE Investigators. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. J Am Med Assoc 1991;266:528-532.
28. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med I 1996; 312: 1637-1641.
29. Caramelli B, Tranchesi B Jr, Gebara OCE, Ferreira de Sa LC, Pileggi FJC. Retinal haemorrhage after thrombolytic therapy. Lancet 1991; 337: 1356-1357.
30. Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash Gl, Vahanian A, Topol EJ, Califf RM for the GUSTO-1 Investigators. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol 1997; 30: 1606-1610.
31. Fava S, Azzopardi J, Agius Muscat H, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 1993; 16: 1615-1618.
32. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993; 70: 530-536.
33. Lew AS, Hod H, Cercek B, Shah PK, Ganz W. Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. Am J Cardiol 1987; 59: 1-5.
34. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336: 847-860.
35. Yudkin JS. Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nilhilist. Diabetologia 1996; 39: 1407-1408.
36. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
37. Yudkin JS. Which diabetic patients should be taking aspirin? Br Mod J 1995; 311: 641-642.
38. Di Minno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-891.
39. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 2. Mortality results. Diabetes 1970; 19 (suppl 2): 785-830.
40. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
41. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L on behalf of the DIGAMI Study Group. A randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
42. Malmberg K for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997; 314: 1512-1515.
43. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in Type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Med 1993; 10: 27-32.
44. Engler RL, Yellon DM. Sulfonylurea KATP blockade in Type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996; 94: 2297-2301.
45. Yudkin JS, Oswald GA. Hyperglycaemia, diabetes and myocardial infarction. Diabetic Med 1987; 4: 13-18.
46. Oswald GA, Smith CCT, Betteridge DJ, Yudkin JS. Determinant and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J 1986; 293: 917-922.